由Bruceine D对Trop2进行向,通过阻断Trop2/β-catenin正反循环,抑制乳腺癌转移
Wenjuan Tang1, Yu Hu1, Kaihui Tu1
1School of Pharmacy, Health Science Center, Xi'an Jiaotong University, Xi'an 710061, China; State Key Laboratory of Shaanxi for Natural Medicines Research and Engineering, Xi'an 710061, China.
布鲁塞因D通过稳定β-catenin来抑制Trop2,这是一种促进乳腺癌转移的蛋白质. 这种小分子阻断转移并改善存活率,提供了一种新的治疗策略.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- 与瘤相关的信号转换器2 (Trop2) 在固体瘤中表达,并用于抗体-药物结合体.
- Trop2在乳腺癌进展和向小分子中的作用尚不清楚.
研究的目的:
- 选针对 Trop2 的小分子.
- 研究Trop2抑制在乳腺癌中的药理作用和分子机制.
主要方法:
- 通过细胞膜染色学识别的小分子Trop2抑制剂,并通过热转移试验验证.
- 使用RNA-seq,入侵试验,殖民地形成和转移模型评估的药理效应.
- 通过免疫沉,质谱学和西式涂抹来阐明分子机制.
主要成果:
- 布鲁塞因D (BD) 被确定为Trop2抑制剂,在乳腺癌中具有抗转移作用.
- BD与Trop2的Lys307和Glu310残留物结合,破坏了Trop2/β-catenin循环.
- 通过减少β-catenin核转移,抑制EMT和ECM重塑,减少肺部殖民,BD抑制转移.
结论:
- Trop2通过稳定β-catenin促进乳腺癌,支持其促进瘤的作用.
- 布鲁塞因D在临床前模型中显示出抗转移潜力和改善生存率.
- 布鲁塞因D是Trop2向乳腺癌治疗的有希望的候选人.
更多相关视频
10:32Combined Use of Tail Vein Metastasis Assays and Real-Time In Vivo Imaging to Quantify Breast Cancer Metastatic Colonization and Burden in the Lungs
Published on: December 19, 2019
07:13Initiation of Metastatic Breast Carcinoma by Targeting of the Ductal Epithelium with Adenovirus-Cre: A Novel Transgenic Mouse Model of Breast Cancer
Published on: March 26, 2014
相关概念视频
Targeted Cancer Therapies
There are several types of targeted therapies against...
Metastasis
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Canonical Wnt Signaling Pathway
Non-Canonical Wnt Signaling Pathways
Mitogens and the Cell Cycle
